No improvement of functional and histological outcome after application of the metabotropic glutamate receptor 5 agonist CHPG in a model of endothelin-1-induced focal ischemia in rats.
The role of group I metabotropic glutamate receptors (mGluRs) in neurodegeneration is as yet unclear as mGluR1/5 antagonists and agonists yielded contradictory effects in different disease models. In the present study, we examined the neuroprotective potency of the selective mGluR5 agonist, (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG), in endothelin-1(ET-1)-induced focal ischemia in rats. In addition to the effect of CHPG on the histologically defined infarct size, we studied its influence on sensorimotor impairments in the ladder rung walking test at late time points up to 4 weeks after the ischemic insult. Rats were treated i.c.v. with an injection of 1mM CHPG beginning 10min after the application of ET-1. Histological analyses 4 weeks after ET-1-induced ischemia demonstrated only a small, insignificant reduction in infarct size after CHPG application. In accordance with this result, there were no significant effects of the used CHPG concentration on sensorimotor impairments in the ladder rung walking test. In conclusion, our data point to the restricted value of CHPG as a neuroprotectant after transient focal ischemia and to the importance of evaluating neuroprotective effects at late post-ischemic time points.
Riek-Burchardt
M
M
Research Institute for Applied Neurosciences (FAN gGmbH), Leipziger Strasse 44, 39120 Magdeburg, Germany. riek@ifn-magdeburg.de
Henrich-Noack
P
P
Reymann
K G
KG
D000818:Animals; D001522:Behavior, Animal; D020520:Brain Infarction / Q000188:drug therapy / Q000209:etiology; D004195:Disease Models, Animal; D019332:Endothelin-1; D018690:Excitatory Amino Acid Agonists / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007511:Ischemia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology*; D008297:Male; D010648:Phenylacetates / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
C107349:2-chloro-5-hydroxyphenylglycine; D019332:Endothelin-1; D018690:Excitatory Amino Acid Agonists; D010648:Phenylacetates; D005998:Glycine